The term that keeps coming up when you talk to Republican staffers in the House of Representatives about their 2011 agenda is: oversight. “I...

Remember the flap over candidates throwing allies, staff and pastors “under the bus?” It may seem like an eon; but it is only a little over ...

With all of the movement in Washington on the confirmations of HHS Secretary and Deputy Secretary Kathleen Sebelius and Bill Corr, respectiv...

We've heard from a few people that the next CMS Administrator has been chosen by the Obama transition team. We're sure the one name ...

Ah, awards season. Why should film critics have all the fun? And voting! It's not just for presidential elections. This year your IN VIV...

You probably remember when Tom Scully was the head of the Centers for Medicare and Medicaid Services. If you do, you may also remember his r...

We didn't wait for the election to start the speculation about who might play an important role in an Obama Administration. But now that...

With the actual election almost here, we figure we’d provide you with a few shortlists of possible candidates for three key positions under ...

Genentech will get a reprieve from lawmakers investigating the company’s pricing practices for its age-related macular degeneration drug ran...

Parallel reviews by the Food & Drug Administration and the Centers for Medicare & Medicaid Services may be just around the corner. A...

"It's a major award!" Not many creatures stirring this pre-holiday weekend, but we couldn't resist keeping up our weekly ...

If you thought the battle over Lucentis and Avastin was confined to FDA, CMS and NIH, you’re wrong. Now Congress is jumping into the fray in...

The primary concern of Day 1 of the FDA/CMS Summit was just how bad for the industry are the unofficial tollgates of a more safety-consciou...

If you attended our FDA/CMS Summit last week, it was great seeing you. If you missed it, shame on you. The keynote address by Cleveland Clin...

Whoever said actions speak louder than words hasn’t been paying attention to the regulatory response to drug safety issues involving the ane...

If you have been reading the IN VIVO Blog you know what we think. But why trust us? That's why we've lined up a bunch of top R&...

To no one’s surprise, sales of Amgen’s flagship anemia product darbepoetin ( Aranesp ) dropped sharply in the third quarter, 23% worldwide, ...

Rep. Stark is smiling; Amgen isn't Amgen Inc.’s uphill climb to reverse restrictive coverage policies for darbepoetin ( Aranesp ) just ...

FDA Commissioner von Eschenbach: Whose Side is He On? That sigh of relief you heard on Tuesday came from Amgen and Johnson & Johnson, wh...

Did you ever have a recurring nightmare? That is what Amgen Inc. and Johnson & Johnson want to avoid next week when another panel of exp...